BGI Genomics (华大基因)

BGI Genomics Home Test Detects Precancerous Polyp

A news report highlights how a home stool test, facilitated by BGI Genomics' technology, helped detect a 2cm polyp that posed a significant risk of developing into colon cancer. The individual, Mr. Liu from Harbin, was able to identify this precancerous lesion early, averting a potential cancer diagnosis and emphasizing the importance of accessible screening methods.

China Launches National R&D Program for Nanopore Sequencing in Pathogen Detection

A national key R&D program was launched on March 16, 2026, to accelerate the application of nanopore sequencing in the field of pathogen infection detection. This initiative aims to enhance the speed and accuracy of identifying infectious agents, which is crucial for public health response and disease control. The program will foster innovation and collaboration in genomic sequencing technologies for medical diagnostics.

China Launches National Nanopore Sequencing Project for Pathogen Infections

A national major science and technology project has been launched to accelerate the application of nanopore sequencing in the field of pathogen infection. This initiative aims to leverage advanced sequencing technology for improved diagnostics and research in infectious diseases, contributing to public health preparedness and response capabilities.

BGI Genomics Reveals cfDNA Genetic Code for Liquid Biopsy

BGI Genomics, in collaboration with Wuhan Children's Hospital and others, has revealed the 'genetic code' of cfDNA's intrinsic characteristics. This breakthrough opens new avenues for the precision of liquid biopsies, particularly in cancer early screening and non-invasive prenatal testing (NIPT). The findings shed light on the 'fragmentomics' of cfDNA.

BGI Reveals cfDNA 'Genetic Code' Advancing Liquid Biopsy Precision

BGI Genomics, in collaboration with Wuhan Children's Hospital and others, has published research on March 11, 2026, revealing the intrinsic characteristics of cell-free DNA (cfDNA) as a 'genetic code.' This breakthrough offers a new pathway for the precision of liquid biopsies, which are used in non-invasive prenatal testing (NIPT) and early cancer screening. The findings address a long-standing question about cfDNA fragmentomics.